Profile picture of Adam Stirling

Dr Adam Stirling

Profile picture of Adam Stirling

MBBS(Hons), FRACP

Medical Oncologist
Call
Referrals

Dr Adam Stirling is a confident, personable doctor who cares for his patients with compassion, kindness and understanding. He believes in going above and beyond to support his patients, and putting their mind at ease during difficult times. Dr Stirling understands that cancer affects the whole family, and seeks to communicate in open and honest language with his patients and their loved ones.

Biography

Dr Adam Stirling is an experienced medical oncologist at Icon Cancer Centre Chermside, Wesley and North Lakes. In 2003 he attained his Bachelor of Medicine, Bachelor of Surgery (MBBS) with Honours at The University of Queensland. Dr Stirling completed his general internal medicine training in 2007, followed by the completion of his specialist medical oncology training at The Royal Brisbane and Women’s Hospital, Princess Alexandra Hospital and Mater Hospitals. In 2011 he commenced private practice with Icon Cancer Centre.

With a strong career background in cutting-edge research, Dr Stirling continues to pursue advances in cancer treatment through clinical trials into novel anti-cancer therapeutics and treatment strategies. He has published articles and lectured extensively in the areas of respiratory malignancies. Dr Stirling is a senior lecturer at The University of Queensland – Faculty of Medicine, and sits as an independent advisor on a number of advisory boards as well as steering groups for research into various malignancies. He maintains a strong focus on early phase clinical trials with Icon Cancer Foundation.

His clinical experience covers a broad range of solid tumour malignancies with a special interest in lung cancer, colorectal cancer, breast cancer, genitourinary cancer and melanoma.

Research

Publications

  • Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. de Bono, J. S., Mehra, N., Scagliotti, G. V., Castro, E., Dorff, T., Stirling, A., Stenzl, A., Fleming, M. T., Higano, C. S., Saad, F., Buttigliero, C., van Oort, I. M., Laird, A. D., Mata, M., Chen, H. C., Healy, C. G., Czibere, A., & Fizazi, K.  The Lancet. Oncology, 2021; 22(9), 1250–1264.

  • Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. F. Saad, J.de Bono, P. Barthélémy, T. Dorff, N. Mehra, G. Scagliotti, A. Stirling, J. Machiels, V. Renard, M. Maruzzo, C. Higano, H. Gurney, C. Healy, H. Bhattacharyya, B. Arondekar, A. Niyazov & K. Fizazi. European Urology, 2022.

  • Abstract CT031: TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)– Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity. J. de Bono, N. Mehra, D. Laird, E. Castro, P. Barthelemy, R. Delva, G. Scagliotti, M. Maruzzo, A. Stirling, J. Machiels, H. Dumez, V. Renard, J. Hopkins, L. Albacker, H. Chen, C. Healy, J. Chelliserry, T. Dorff & K. Fizazi. Cancer Res, 2022; 82(12).

  • TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity. T. Dorff, K. Fizazi, D. Laird, P. Barthelemy, R. Delva, M. Maruzzo, A. Stirling, J. Machiels, H. Dumez, V. Renard, J. Hopkins, H. Chen, C. Healy, J. Chelliserry, I. van Oort, G. Scagliotti, J.de Bono, N. Mehra. Journal of Clinical Oncology, 2022; 40(6), 157.

  • Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. J.de Bono, N. Mehra, G. Scagliotti, E. Castro, T. Dorff, A. Stirling, A. Stenzl, M. Fleming, C. Higano, F. Saad & C. Buttiglier. The Lancet Oncology, 2021; 22(9), 1250-1264.

Special Interests

Dr Adam Stirling accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Colorectal cancer
  • Genitourinary cancer
  • Lung cancer
  • Melanoma

Languages spoken

  • English

Visiting Locations

  • St Andrew’s War Memorial Hospital
  • St Vincent’s Private Hospital Northside
  • Mater Private Hospital

Affiliations & Memberships

  • Australian Medical Association (AMA)
  • American Society of Clinical Oncology (ASCO)
  • Clinical Oncological Society of Australia (COSA)
  • European Society of Medical Oncology (ESMO)
  • Medical Oncology Group of Australia (MOGA)
  • Private Cancer Physicians of Australia (PCPA)
  • Royal Australian College of Physicians (RACP)

Publications

  • Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. de Bono, J. S., Mehra, N., Scagliotti, G. V., Castro, E., Dorff, T., Stirling, A., Stenzl, A., Fleming, M. T., Higano, C. S., Saad, F., Buttigliero, C., van Oort, I. M., Laird, A. D., Mata, M., Chen, H. C., Healy, C. G., Czibere, A., & Fizazi, K.  The Lancet. Oncology, 2021; 22(9), 1250–1264.

  • Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. F. Saad, J.de Bono, P. Barthélémy, T. Dorff, N. Mehra, G. Scagliotti, A. Stirling, J. Machiels, V. Renard, M. Maruzzo, C. Higano, H. Gurney, C. Healy, H. Bhattacharyya, B. Arondekar, A. Niyazov & K. Fizazi. European Urology, 2022.

  • Abstract CT031: TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)– Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity. J. de Bono, N. Mehra, D. Laird, E. Castro, P. Barthelemy, R. Delva, G. Scagliotti, M. Maruzzo, A. Stirling, J. Machiels, H. Dumez, V. Renard, J. Hopkins, L. Albacker, H. Chen, C. Healy, J. Chelliserry, T. Dorff & K. Fizazi. Cancer Res, 2022; 82(12).

  • TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity. T. Dorff, K. Fizazi, D. Laird, P. Barthelemy, R. Delva, M. Maruzzo, A. Stirling, J. Machiels, H. Dumez, V. Renard, J. Hopkins, H. Chen, C. Healy, J. Chelliserry, I. van Oort, G. Scagliotti, J.de Bono, N. Mehra. Journal of Clinical Oncology, 2022; 40(6), 157.

  • Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. J.de Bono, N. Mehra, G. Scagliotti, E. Castro, T. Dorff, A. Stirling, A. Stenzl, M. Fleming, C. Higano, F. Saad & C. Buttiglier. The Lancet Oncology, 2021; 22(9), 1250-1264.

Search

Contact us
Become a patient